Carlsmed, Inc. (CARL) — SEC Filings
Carlsmed, Inc. (CARL) — 6 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 2 10-Q, 2 8-K, 1 S-1/A.
View Carlsmed, Inc. on SEC EDGAR
Overview
Carlsmed, Inc. (CARL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: CARLSMED, INC. (CARL) reported a significant increase in revenue for the three and nine months ended September 30, 2025. Revenue for the three months surged to $13.074 million from $6.590 million in the prior year, a 98.4% increase. For the nine months, revenue more than doubled to $35.346 million f
Sentiment Summary
Across 6 filings, the sentiment breakdown is: 4 neutral, 2 mixed. The dominant filing sentiment for Carlsmed, Inc. is neutral.
Filing Type Overview
Carlsmed, Inc. (CARL) has filed 2 10-Q, 2 8-K, 1 S-1/A, 1 S-1 with the SEC between Jun 2025 to Nov 2025.
Recent SEC Filings (6)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 6, 2025 | 10-Q | CARLSMED Revenue Nearly Doubles, IPO Boosts Cash Amid Widening Losses | medium |
| Oct 30, 2025 | 8-K | Carlsmed, Inc. Enters Material Definitive Agreement | medium |
| Aug 28, 2025 | 10-Q | CARLSMED Doubles Revenue, IPO Boosts Liquidity Amid Widening Losses | medium |
| Jul 24, 2025 | 8-K | CARLSMED, INC. Files 8-K with Corporate Updates | low |
| Jul 15, 2025 | S-1/A | Carlsmed Files S-1/A for IPO, Eyes Public Market Debut | medium |
| Jun 26, 2025 | S-1 | S-1 Filing |
Risk Profile
Risk Assessment: Of CARL's 5 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 1 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $35.346M |
| Net Income | -$21.021M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $115.373M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Michael Cordonnier
- R. John Hensley
- B. Shayne Kennedy
Industry Context
CARLSMED operates in the healthcare technology or medical device sector, an industry characterized by rapid innovation, significant R&D investment, and a highly regulated environment. Companies in this space often experience high revenue growth potential driven by new product introductions and market adoption, but also face intense competition and the need for substantial capital to fund growth and navigate regulatory hurdles.
Top Tags
Medical Devices (3) · IPO (3) · Spine Surgery (2) · Revenue Growth (2) · Net Loss (2) · Surgical Technology (2) · AI in Healthcare (1) · material-agreement (1) · financial-obligation (1) · Liquidity (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for Q3 2025 | $13.074M | Increased 98.4% from $6.590M in Q3 2024 |
| Revenue for nine months ended Sep 30, 2025 | $35.346M | Increased 99.0% from $17.757M in the prior year period |
| Net loss for Q3 2025 | $8.526M | Widened from $7.813M in Q3 2024 |
| Net loss for nine months ended Sep 30, 2025 | $21.021M | Widened from $19.537M in the prior year period |
| Proceeds from Initial Public Offering | $93.465M | Net of underwriting discounts and commissions |
| Cash and cash equivalents as of Sep 30, 2025 | $115.373M | Increased from $40.125M at Dec 31, 2024 |
| Sales and marketing expenses for nine months ended Sep 30, 2025 | $24.218M | Increased from $15.092M in the prior year period |
| General and administrative expenses for nine months ended Sep 30, 2025 | $11.715M | Increased from $6.068M in the prior year period |
| Shares of common stock outstanding | 26,592,908 | As of November 3, 2025 |
| Commission File Number | 001-42756 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 83-1081863 | Company's tax identification number. |
| Q2 2025 Revenue | $12.083M | Doubled from $6.081M in Q2 2024, indicating strong product adoption. |
| H1 2025 Revenue | $22.272M | Increased from $11.167M in H1 2024, showing consistent growth. |
| Q2 2025 Net Loss | $6.766M | Widened from $6.277M in Q2 2024, reflecting increased operating expenses. |
| H1 2025 Net Loss | $12.495M | Increased from $11.724M in H1 2024, despite revenue growth. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Carlsmed, Inc. (CARL)?
Carlsmed, Inc. has 6 recent SEC filings from Jun 2025 to Nov 2025, including 2 10-Q, 2 8-K, 1 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CARL filings?
Across 6 filings, the sentiment breakdown is: 4 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Carlsmed, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Carlsmed, Inc. (CARL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Carlsmed, Inc.?
Key financial highlights from Carlsmed, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CARL?
The investment thesis for CARL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Carlsmed, Inc.?
Key executives identified across Carlsmed, Inc.'s filings include Michael Cordonnier, R. John Hensley, B. Shayne Kennedy.
What are the main risk factors for Carlsmed, Inc. stock?
Of CARL's 5 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Carlsmed, Inc.?
Forward guidance and predictions for Carlsmed, Inc. are extracted from SEC filings as they are enriched.